Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003741 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003741: Completed Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT00003741 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003741, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients with refractory anaplastic large cell lymphoma or Hodgkin's lymphoma.
Interventions
- BIOLOGICAL monoclonal antibody HeFi-1
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
What the finished NCT00003741 record still lists
NCT00003741 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody HeFi-1 is the first listed.
NCT00003741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003741 about?
NCT00003741 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients with refractory anaplastic large cell lympho...
What is the current status of trial NCT00003741?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00003741?
The interventions under investigation include: monoclonal antibody HeFi-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003741?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia